Local Regulatory Experts
Connect with regulatory affairs consultancies specializing in this region.
Qualtech Consulting Corporation
Taiwan, China, Japan, Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Australia, Germany, Korea, Thailand, USA
A specialized medical device consulting firm offering a one-stop solution for complex global regulatory challenges. We offer real-time regulatory and clinical support, local representation, and QMS services across 13 markets, ensuring efficient market entry and compliance.
Cobridge Co., Ltd.
Tokyo, Japan
We assist medical device companies with the medical device registration and approval in Japan. Regulatory consulting services and DMAH services for foreign manufacturers to enter Japanese market.
MDREX, Medical Device, Digital Health Consulting Group
Seoul, Republic of Korea (HQ), Japan Office
We offer total solutions for market entry in South Korea and global expansion (e.g., Japan, USA, Europe). Key areas include product approval, reimbursement listings (HIRA), and Quality System certification (KGMP). They are particularly strong in innovative products like SaMD, medical wearables, and 3D printing for medical use, and provide in-depth expertise in cybersecurity and clinical trial planning.
CMIC Holdings Co., Ltd.
Tokyo, Japan (HQ), Osaka, Japan, Beijing, China, Seoul, South Korea, Taipei, Taiwan, Singapore, New York, USA, London, UK, Frankfurt, Germany, Sydney, Australia
We operate globally, specializing in accelerating the development, manufacturing, and commercialization of drugs and medical devices. Their expertise spans Phase I to IV clinical trials, regulatory affairs, quality assurance, and manufacturing, with a strong focus on the Japanese and Asian markets. Key services include clinical operations (CRO), manufacturing (CDMO/CMO), site management (SMO), and comprehensive health analysis and solutions.
June 1, 2025
Approximately 5 minutes
Standards for Marketing Approval of Antivertigo Medicines in Japan
Standards for Marketing Approval of Antivertigo Medicines (Japan)
The Standards for Marketing Approval of Antivertigo Medicines were issued by the Pharmaceuticals and Medical Devices Agency of Japan as Notification PB No.381 on June 1, 1984. These standards specify regulatory criteria for oral medications intended to prevent or relieve symptoms associated with motion sickness, including dizziness, nausea, and headache. Preparations that do not conform to these criteria require submission of efficacy and safety data for review. (PMDA, 000272494.pdf).
Scope
The standards apply to oral antivertigo medicines for relief or prevention of motion sickness symptoms. Traditional Kampo medicine formulas are excluded. (PMDA, 000272494.pdf).
Active Ingredients
The types of permissible active ingredients and combination rules are outlined in Table 1. At least one ingredient from Column I or Group 1 of Column II must be included. Ingredients from different columns and groups may be combined following specified limits, and vitamins may be added where justified. (PMDA, 000272494.pdf).
Quantities of Active Ingredients
For each listed active ingredient, maximum single and daily doses are specified in Table 1. Minimum dose limits and combination dose limits are defined depending on the grouping of the ingredients; for example, when two Column I ingredients are combined, the sum of fractional doses must be between 0.5 and 1 of the maximum single dose. (PMDA, 000272494.pdf).
Dosage Forms
Approved dosage forms include capsules, granules, pills, fine granules, powders, tablets (including chewable tablets) and oral liquids. (PMDA, 000272494.pdf).
Dosage and Administration
- Dosage is by oral administration 1–3 times per day (except preparations with dimenhydrinate, which may be dosed 1–4 times per day).
- Administration times and intervals (at least 4 hours apart for more than one dose per day) must be clearly indicated.
- Children under 3 years are generally not approved for use; certain active ingredients have higher age limits (e.g., ethyl aminobenzoate is not approved under 6 years, promethazine compounds are not approved under 15 years).
- For pills and tablets larger than 6 mm, dosage is not approved for children under 5 years.
- Age‑based dose adjustment coefficients are provided in Table 2. (PMDA, 000272494.pdf).
Indications
Approved indications are prevention and relief of dizziness, nausea, and headache associated with motion sickness. (PMDA, 000272494.pdf).
Packaging Units
For oral liquid formulations, container volume should generally be the amount for a single dose and not exceed 30 mL. (PMDA, 000272494.pdf).
Summary
These standards define the regulatory framework for marketing approval of antivertigo medicines in Japan, ensuring safety and efficacy through criteria on active ingredients, dose limits, dosage forms, administration, indications, and packaging. (PMDA, 000272494.pdf).
Have a Question?
Ask our experts about this topic. We'll do our best to respond to your question.
Related Articles
Approximately 5 minutes
Japan: Standards for Marketing Approval of OTC Cold Remedies (MHLW Notification PB No.28)
A practical overview of Japan’s OTC cold remedy approval standards: permitted dosage forms, dosing/age limits, allowable indications, and key constraints that shape formulation and labeling.
Approximately 5 minutes
Standards for Marketing Approval of Cold Remedies in Japan
Regulatory standards for OTC cold remedies in Japan
Approximately 5 minutes
Standards for Marketing Approval of Antitussives and Expectorants in Japan
Regulatory criteria for OTC antitussives and expectorants in Japan
Approximately 5 minutes
Standards for Marketing Approval of Oral Remedies for Rhinitis in Japan
Regulatory standards for oral rhinitis remedies in Japan
Approximately 5 minutes
Standards for Marketing Approval of Gastrointestinal Medicines in Japan
Regulatory criteria for OTC gastrointestinal medicines in Japan
Approximately 5 minutes
Standards for Marketing Approval of Laxatives in Japan
Regulatory criteria for OTC laxatives in Japan